http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 30 Jun 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InflaRx+N.V.++++++++++++++For%3A+Jun+30/26713547.html si-local-file:///var/storage/secattach/20260630/26713547.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InflaRx+N.V.++++++++++++++For%3A+Jun+30/26713547.html Tue, 30 Jun 2026 16:05:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InflaRx+N.V.++++++++++++++For%3A+Jun+30/26713547.html si-local-file:///var/storage/secattach/20260630/26713547.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InflaRx+N.V.++++++++++++++For%3A+Jun+30/26713547.html Tue, 30 Jun 2026 16:05:00 -0400 IFRX O.32273423 http://www.streetinsider.com/Corporate+News/InflaRx+reviews+AAV+strategy+after+EMA+moves+to+revoke+Tavneos/26709567.html <p>InflaRx N.V. (Nasdaq: IFRX) said it is assessing the feasibility of broadening its development strategy for ANCA-associated vasculitis (AAV) in Europe after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended revoking the marketing authorization for Tavneos in the European Union on June 26, 2026.</p><p>The company said it plans to engage with the EMA regarding two of its compounds: vilobelimab, an anti-C5a antibody approved in Europe under exceptional circumstances as Gohibic for SARS-CoV-2-induced acute respiratory distress syndrome, and izicopan, an oral C5a receptor inhibitor currently in Phase 2 planning for AAV. InflaRx said the Phase 2 planning http://www.streetinsider.com/Corporate+News/InflaRx+reviews+AAV+strategy+after+EMA+moves+to+revoke+Tavneos/26709567.html Tue, 30 Jun 2026 07:31:07 -0400 IFRX http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Press+Releases/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html <ul type="disc"><li style="text-align:left;">InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)</li><li style="text-align:left;">The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients</li><li style="text-align:left;">Previously announced Phase 2 planning with izicopan in AAV continues uninterrupted<br/></li></ul> <p align="justify"><b>Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has http://www.streetinsider.com/Globe+Newswire/InflaRx+Assessing+Feasibility+of+Broadened+Strategy+for+ANCA%E2%80%91Associated+Vasculitis+in+Europe+Following+EMA+Recommendation+on+Tavneos/26709543.html Tue, 30 Jun 2026 07:30:00 -0400 A.42688798 A.50202117 A.50214048 A.60012002 IFRX O.00657036 O.00817244 O.32273423 O.37382289 O.69857460 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+Farallon+Capital+Partners%2C+L.P./26490555.html si-local-file:///var/storage/secattach/20260514/26490555.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+Farallon+Capital+Partners%2C+L.P./26490555.html Thu, 14 May 2026 08:28:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+Farallon+Capital+Partners%2C+L.P./26490555.html si-local-file:///var/storage/secattach/20260514/26490555.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+Farallon+Capital+Partners%2C+L.P./26490555.html Thu, 14 May 2026 08:28:00 -0400 IFRX O.32273423